Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy

References

• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
   PubMed Web of Science ®Google Scholar
• Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37–49.
   PubMed Web of Science ®Google Scholar
• Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg. 2006;244:524–535.
   PubMed Web of Science ®Google Scholar
• Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the international registry of lung metastases. J Thorac Oncol. 2011;6:1373–1378.
   PubMed Web of Science ®Google Scholar
• House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744–752.
   PubMed Web of Science ®Google Scholar
• Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–338.
   PubMed Web of Science ®Google Scholar
• Herold CJ, Bankier AA, Fleischmann D. Lung metastases. Eur Radiol. 1996;6:596–606.
   PubMed Web of Science ®Google Scholar
• McKenna RJ, McKenna RJ Jr. Patterns of pulmonary metastases. An orthopedic hospital experience. In: Weiss L, Gilbert HA, editors. Pulmonary metastasis. Boston (GK): Hall & Co.; 1978. p. 1626–1634.
   Google Scholar
• McCormack PM, Bains MS, Martini N. Surgical management of pulmonary metastases. In: Shiu M, Brennan M, editors. Surgical management of soft tissue sarcoma. Philadelphia (PA): Lea & Febinger; 1989. p. 70–77.
   Google Scholar
• Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:348–353.
   PubMed Web of Science ®Google Scholar
• Louie AV, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis. Int J Radiat Oncol Biol Phys. 2011;81:964–973.
   PubMed Web of Science ®Google Scholar
• Van der Voort Van Zyp NC, Prévost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91:296–300.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol. 2012;102:383–387.
   PubMed Web of Science ®Google Scholar
• Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases a systematic review. J Thorac Oncol. 2010;5:1091–1099.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, Voort van Zyp CMG, Verhoef C, et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys. 2015;91:337–343.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, van de Pol M. The cyberknife radiosurgery system for lung cancer. Expert Rev Med Devices. 2012;9:465–475.
   PubMed Web of Science ®Google Scholar
• Hoogeman M, Prevost JB, Nuyttens J, et al. Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. Int J Radiat Oncol Biol Phys. 2009;74:297–303.
   PubMed Web of Science ®Google Scholar
• Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015;114:155–160.
   PubMed Web of Science ®Google Scholar
• Ricardi U, Filippi AR, Guarnieri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75:77–81.
   PubMed Web of Science ®Google Scholar
• Rieber J, Streblow J, Uhlmann L, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—a pooled analysis of the German working group “stereotactic radiotherapy”. Lung Cancer. 2016;97:51–58.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Klement RJ, Allgauer M, et al. Local tumor control probability modelling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol. 2016;118:485–491.
   PubMed Web of Science ®Google Scholar
• van der Voort van Zyp NC, Hoogeman MS, van de Water S, et al. Clinical introduction of Monte Carlo treatment planning: a different prescription dose for non-small cell lung cancer according to tumor location and size. Radiother Oncol. 2010;96:55–60.
   PubMed Web of Science ®Google Scholar
• Wilcox EE, Daskalov GM, Lincoln H, et al. Comparison of planned dose distributions calculated by Monte Carlo and Ray-Tracing algorithms for the treatment of lung tumors with cyberknife: a preliminary study in 33 patients. Int J Radiat Oncol Biol Phys. 2010;77:277–284.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for sub-distribution of competing risk. J Am Stat Assoc. 1999;94:496–609.
   Web of Science ®Google Scholar
• Navarria P, Ascolese AM, Stefano Tomatis S, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9:91.
   PubMed Web of Science ®Google Scholar
• Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631.
   PubMed Web of Science ®Google Scholar
• Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease – influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123:227–233.
   PubMed Web of Science ®Google Scholar
• El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumors after induction chemotherapy. Br J Cancer. 2003;89:2184–2189.
   PubMed Web of Science ®Google Scholar
• Landriscina M, Maddalena F, Laudiero G, et al. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal. 2009;11:2701–2716.
   PubMed Web of Science ®Google Scholar
• Fink MK, Kleeberg UR, Bartels S. Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon. Oncologist. 2015;20:88.
   PubMed Web of Science ®Google Scholar
• Siva S, Kron T, Bressel M, et al. A randomised phase II trial of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung (TROG 13.01 SAFRON II). BMC Cancer. 2016;16:1.
   Web of Science ®Google Scholar
• Solberg TD, DeMarco JJ, Holly FE, et al. Monte Carlo treatment planning for stereotactic radiosurgery. Radiother Oncol. 1998;49:73–84.
   PubMed Web of Science ®Google Scholar
• Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thoracic Dis. 2014;6:369–374.
   PubMed Web of Science ®Google Scholar
• Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101:255–259.
   PubMed Web of Science ®Google Scholar
• Widder J, Klinkenberg TJ, Ubbels JF, et al. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol. 2013;107:409–413.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Guerrera F, Badellino S, et al. Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer. Clin Oncol (R Coll Radiol). 2016;28:505–512.
   PubMed Web of Science ®Google Scholar